Chronic Kidney Disease Prognosis Consortium

Chronic Kidney Disease Prognosis Consortium
Name	Chronic Kidney Disease Prognosis Consortium
Formation	2007
Type	Research consortium
Headquarters	Global
Leader title	Coordinating investigators

Chronic Kidney Disease Prognosis Consortium

The Chronic Kidney Disease Prognosis Consortium is a global research collaboration that investigates outcomes of chronic kidney disease through pooled analyses of cohort studies and clinical trials. It brings together investigators from institutions such as the National Institutes of Health, World Health Organization, Centers for Disease Control and Prevention, Oxford University, and Harvard University to improve prognostic models, risk stratification, and guidelines for kidney disease management. The consortium informs policy bodies including the American Heart Association, European Society of Cardiology, and Kidney Disease: Improving Global Outcomes while engaging with research funders such as the Wellcome Trust and Bill & Melinda Gates Foundation.

Overview

The consortium functions as a multicenter network uniting cohorts like the Framingham Heart Study, Atherosclerosis Risk in Communities Study, Multi-Ethnic Study of Atherosclerosis, Nurses' Health Study, and Jackson Heart Study with trial datasets from groups such as the Action to Control Cardiovascular Risk in Diabetes and Systolic Blood Pressure Intervention Trial. It produces pooled estimates on outcomes tied to kidney function measures, collaborating with statisticians from University of Cambridge, Stanford University, Johns Hopkins University, Imperial College London, and University of Toronto and clinicians from Mayo Clinic, Cleveland Clinic, Massachusetts General Hospital, and Karolinska Institutet.

History and Formation

Founded in 2007 through discussions among investigators at meetings involving the International Society of Nephrology, American Society of Nephrology, and representatives from the European Renal Association–European Dialysis and Transplant Association, the consortium formalized data sharing agreements echoing precedents set by the Global Burden of Disease collaboration and the Consortium of Metabolic Studies. Key early contributors included research groups affiliated with UCLA, University of Michigan, McMaster University, Seoul National University, and Peking University.

Objectives and Scope

Primary objectives include improving risk prediction for end-stage renal disease, cardiovascular events, and mortality using estimated glomerular filtration rate and albuminuria data from diverse populations such as cohorts in Brazil, South Africa, India, China, and Mexico. The consortium aims to influence clinical guidance from bodies like the National Institute for Health and Care Excellence and American College of Physicians and to harmonize measures across population studies following protocols used by the Global Cardiovascular Research Network.

Methodology and Data Sources

Methodology centers on individual participant data meta-analyses and pooled cohort analyses using harmonized variables derived from longitudinal studies including the Rotterdam Study, British Regional Heart Study, Danish Diet, Cancer and Health study, CARDIA study, and multicountry registries such as the United States Renal Data System and European Renal Association Registry. Analytical frameworks incorporate survival analysis techniques common to research at Princeton University, University of Chicago, Duke University, and Yale University with quality control modeled after consortia like the Cohorts for Heart and Aging Research in Genomic Epidemiology.

Key Findings and Impact

Findings have clarified the graded association between reduced kidney function, albuminuria, and risks of myocardial infarction, stroke, heart failure, and all-cause mortality across age groups and ethnicities represented in cohorts such as Hispanic Community Health Study/Study of Latinos and Singapore Chinese Health Study. Results influenced classification systems endorsed by KDIGO and informed risk calculators used in clinics including Johns Hopkins Hospital and Karolinska University Hospital. The consortium’s publications have been cited alongside work from Lancet, New England Journal of Medicine, Journal of the American Medical Association, BMJ, and European Heart Journal.

Collaborations and Funding

Collaborations span academic centers, professional societies like the International Society of Hypertension and Heart Failure Association, and public health agencies including the Agency for Healthcare Research and Quality and European Centre for Disease Prevention and Control. Funding has come from national agencies such as the National Heart, Lung, and Blood Institute, Canadian Institutes of Health Research, Medical Research Council (United Kingdom), and philanthropic sources including the Rockefeller Foundation and Chan Zuckerberg Initiative.

Criticisms and Limitations

Critiques address heterogeneity among cohorts, measurement variation similar to issues debated in the Framingham Heart Study replication literature, and representation gaps for populations from regions discussed at United Nations conferences and in World Bank reports. Methodological limitations include potential confounding and selection bias noted in meta-analytic debates involving groups from Columbia University, University of California, San Francisco, University of Sydney, and Tsinghua University; concerns parallel those raised in multinational collaborations like the Human Genome Project and the Global Alliance for Genomics and Health.

Category:Nephrology research networks